Bicycle finally falls
The company admits defeat with zelenectide.
EAU 2026 – J&J strengthens its bladder hand
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
MAT2A inhibition gets another endorsement
Gilead opting against IDE397 is still good news for Ideaya.
Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
EnGene squares up to J&J
New detalimogene bladder cancer data send the minnow’s stock up 47%.
ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
